SEMA4D and postmenopausal osteoporosis: Administration of an anti-SEMA4D antibody prevents bone loss in a mouse model of postmenopausal osteoporosis and promotes bone formation without affecting osteoclast-mediated bone resorption, suggesting that SEMA4D is a potential therapeutic target for osteoporosis or other low bone mass disorders [68].